Hisamitsu Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
Hisamitsu Pharmaceutical's earnings have been declining at an average annual rate of -4.3%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 1.5% per year. Hisamitsu Pharmaceutical's return on equity is 5.5%, and it has net margins of 9.8%.
Key information
-4.3%
Earnings growth rate
-2.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | 1.5% |
| Return on equity | 5.5% |
| Net Margin | 9.8% |
| Last Earnings Update | 31 Aug 2024 |
Recent past performance updates
Recent updates
Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00
Nov 08
We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt
Nov 04Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations
Oct 17Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing
Sep 16Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 20Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00
Jul 26Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year
Jul 11Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00
Jun 27Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00
Jun 13Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price
Apr 09Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching
Mar 18Revenue & Expenses Breakdown
How Hisamitsu Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 24 | 150,185 | 14,650 | 62,341 | 8,614 |
| 31 May 24 | 145,420 | 14,708 | 59,488 | 8,614 |
| 29 Feb 24 | 141,706 | 13,969 | 57,189 | 8,614 |
| 30 Nov 23 | 139,276 | 14,330 | 53,370 | 9,785 |
| 31 Aug 23 | 135,688 | 13,655 | 52,015 | 9,785 |
| 31 May 23 | 134,033 | 14,160 | 51,445 | 9,785 |
| 28 Feb 23 | 128,330 | 11,742 | 51,314 | 9,785 |
| 30 Nov 22 | 125,411 | 12,962 | 49,586 | 10,613 |
| 31 Aug 22 | 121,261 | 11,160 | 49,943 | 10,613 |
| 31 May 22 | 118,825 | 8,927 | 49,863 | 10,613 |
| 28 Feb 22 | 120,193 | 9,658 | 50,117 | 10,613 |
| 30 Nov 21 | 120,351 | 9,746 | 49,989 | 10,766 |
| 31 Aug 21 | 120,135 | 10,559 | 49,625 | 10,766 |
| 31 May 21 | 117,389 | 11,499 | 48,082 | 10,766 |
| 28 Feb 21 | 114,510 | 9,250 | 47,735 | 10,766 |
| 30 Nov 20 | 122,736 | 8,996 | 50,816 | 10,504 |
| 31 Aug 20 | 130,517 | 14,839 | 51,885 | 10,504 |
| 31 May 20 | 136,641 | 16,894 | 52,951 | 10,504 |
| 29 Feb 20 | 140,992 | 18,694 | 54,371 | 10,504 |
| 30 Nov 19 | 139,912 | 21,295 | 51,017 | 13,032 |
| 31 Aug 19 | 137,425 | 17,594 | 51,664 | 13,032 |
| 31 May 19 | 139,142 | 17,665 | 53,378 | 13,032 |
| 28 Feb 19 | 143,408 | 19,204 | 53,369 | 13,032 |
| 30 Nov 18 | 140,891 | 16,608 | 50,620 | 15,076 |
| 31 Aug 18 | 143,791 | 18,891 | 49,535 | 15,076 |
| 31 May 18 | 145,288 | 18,897 | 49,316 | 15,076 |
| 28 Feb 18 | 147,870 | 19,119 | 50,760 | 15,076 |
| 30 Nov 17 | 145,749 | 17,895 | 50,799 | 14,378 |
| 31 Aug 17 | 144,941 | 20,495 | 49,027 | 14,378 |
| 31 May 17 | 143,853 | 19,540 | 49,273 | 14,378 |
| 28 Feb 17 | 145,925 | 20,395 | 51,156 | 14,378 |
| 30 Nov 16 | 149,298 | 20,806 | 52,197 | 14,965 |
| 31 Aug 16 | 153,871 | 17,694 | 56,497 | 14,965 |
| 31 May 16 | 160,325 | 18,778 | 59,209 | 14,965 |
| 29 Feb 16 | 161,852 | 17,784 | 59,769 | 14,965 |
| 30 Nov 15 | 164,086 | 19,626 | 62,668 | 13,718 |
| 31 Aug 15 | 162,119 | 18,586 | 64,344 | 13,718 |
| 31 May 15 | 158,667 | 18,321 | 64,685 | 13,718 |
| 28 Feb 15 | 156,743 | 18,784 | 64,489 | 13,718 |
| 30 Nov 14 | 150,446 | 16,645 | 64,062 | 13,924 |
| 31 Aug 14 | 150,305 | 17,250 | 63,138 | 13,924 |
| 31 May 14 | 151,326 | 17,841 | 62,325 | 13,924 |
| 28 Feb 14 | 150,635 | 21,357 | 61,243 | 13,924 |
| 30 Nov 13 | 150,544 | 22,976 | 59,712 | 12,662 |
Quality Earnings: 4530 has high quality earnings.
Growing Profit Margin: 4530's current net profit margins (9.8%) are lower than last year (10.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4530's earnings have declined by 4.3% per year over the past 5 years.
Accelerating Growth: 4530's earnings growth over the past year (7.3%) exceeds its 5-year average (-4.3% per year).
Earnings vs Industry: 4530 earnings growth over the past year (7.3%) did not outperform the Pharmaceuticals industry 12.2%.
Return on Equity
High ROE: 4530's Return on Equity (5.5%) is considered low.